peptide · regulated markets
What Peptide FTC Warning Letters Punished in 2026
Last Tuesday a founder asked if her BPC-157 launch was safe to brief. BPC-157 is a short peptide some athletes use for soft-tissue recovery, sold as a research compound. Her creator pick had 20 Marek Health deals on the books. Marek Health is a US testosterone and peptide telehealth clinic. We log 210 Marek Health deals across 32 creators from January 2024 to April 2026. My answer was hold the brief because of the language.
The phrases that pull warning letters cluster into five buckets. A 90-second read catches most of them before the post ships. The FDA published its first big peptide-adjacent sweep in September 2025, warning 30 telehealth companies in one day.
Five trigger phrases that pull a letter
Outcome-guarantee language. Cure, heal, reverse, treat, and fix all pull the same kind of letter. The FDA reads them as drug claims even when the product is sold as a supplement. A safe verb is supports.
Clinical-claim language without a doctor on screen. A creator saying peptides regenerate joint tissue without a physician citing a source lands in the same bucket as a sham cure ad. A board-certified MD gets away with longer claims because the credential is on screen. A fitness creator reading the same line does not.
Compounded-as-equivalent language. Calling a compounded tirzepatide product the same as Mounjaro is a fast lane to a letter. Tirzepatide is the active ingredient in Mounjaro and Zepbound. The FDA put this in writing in its September 2025 GLP-1 Solution letter.
Most teams under-spend on the read and over-spend on the legal cleanup, here is the 90-second language sweep we send peptide brands before the brief ships.
Research-use-only language paired with dosing tips. A caption that says for research purposes only while the host walks through a 250mcg twice-daily protocol cancels the disclaimer. The Department of Defense BPC-157 page lays out why: BPC-157 is an unapproved drug, no matter what the label says.
Weight-loss-amount promises. Lose 20 pounds, drop a dress size, lose one pound a week. These all pull letters. Branded GLP-1 ads carry FDA-cleared labels that bound the claim. Compounded versions do not. The same line is safe on a Wegovy ad and risky on a Mochi Health ad. Mochi Health is a compounded-GLP-1 telehealth brand with 43 deals across 9 creators in our log.
Days to letter and how the escalation runs
The escalation runs in four steps. A post goes live. A sweep or complaint flags it. The FDA sends a quiet contact letter to the brand. If the post stays up, the public warning letter lands next. A settlement, if any, comes months later.
Worried one of your creators is sitting on a flagged phrase right now? Our pre-publish read scans the script, on-screen text, caption, and pinned comment against the five buckets above. We send it back within 48 hours with a green-light or a one-line fix per surface. Free for any peptide brief.
Send us a peptide brief and we will run the read →The window from flagged post to public letter in the September 2025 sweep ran weeks to months. The brand has time to fix the language if it reads the early cue. The cost of missing it is a letter on a government site for the next decade.
The patient cadence is also the trap. A brand that runs four peptide posts a quarter assumes the language is safe. Then the sweep arrives and three quarters of content light up.
Compounded brands vs branded GLP-1 brands
The split between compounded and branded GLP-1 brands is the most important risk line in this category.
Branded GLP-1 drugs, Wegovy and Ozempic for semaglutide, Mounjaro and Zepbound for tirzepatide, have an FDA-cleared label that bounds what a creator can claim. A line that strays past the label triggers a letter, but the path to compliance is well known.
Compounded GLP-1 brands sit inside the 503A pharmacy exception. That is the exact surface the FDA put under enforcement in September 2025 once the tirzepatide shortage resolved. With the shortage gone, the compounding rationale narrowed. In our deal log, the compounded brands carry every kind of letter risk the branded ones do, plus the structural risk of the pathway itself.
- Cure, treat, heal, reverse, and fix used in the on-screen overlay
- Compounded GLP-1 called the same as Ozempic in the caption
- Research-use-only label paired with a dosing protocol in the host read
Across 210 Marek Health deals, 43 Mochi Health deals, and 18 Simple Peptides deals in our sponsor log, the five trigger-phrase buckets show up on the same three surfaces every time.— Internal sponsor-deal log, Jan 2024 to Apr 2026Send me a pre-publish read, free →
Where the FDA looks first on a creator post
The FDA reads three surfaces in order.
The on-screen text overlay is first. Short, public, and easy to screenshot.
The caption and hashtag stack is second. The TRT and Hormone Optimization channel runs 85 peptide-adjacent deals in our log, with caption patterns like #peptides #cjc1295 #tesamorelin #ipamorelin. CJC-1295, tesamorelin, and ipamorelin are growth-hormone-releasing peptides. The hashtags name compounds the brand cannot legally market. The post might survive on its own. The hashtag stack is the trail that finds it.
The host read plus the pinned comment is third. The pinned comment is the highest-risk overlooked spot. Brands park a catch-all not medical advice line there while the host reads a specific dose on camera. The on-camera claim wins in a regulator's read every time.
Four archetypes of peptide creators by risk
Four archetypes show up in our log. They line up cleanly by letter risk.
Credentialed health-care creator. Dr. Taz MD reads disclosures as part of her cadence and carries a board-certified credential on screen. Risk is lowest because the credential bounds what the FDA reads as opinion versus advice.
Podcast host as patient. Mark Bell's Power Project at 384K subscribers with 20 Marek Health deals runs the pattern. The host is on TRT in public. The read is a story, not a clinical claim. Risk is moderate.
Fitness creator as stack recommender. VigorousClips and VigorousSteve run 41 combined peptide deals. Risk is higher because the hashtag stack and the on-camera dose land together.
GLP-1 testimonial creator. Lorraine Kamesha at 59K subscribers runs 22 Orderly Meds deals. Orderly Meds is a compounded GLP-1 telehealth brand. Risk is highest because the post is a weight-loss-amount story tied to a 503A product.
A 5-creator roster blends the gradient. Pulling all five from one archetype concentrates the risk.
Most peptide brands learn this the hard way after the first letter, here is the archetype mix we recommend before the brief ships.
Where We Come In
We read every published peptide and compounded-GLP-1 warning letter against every creator on your shortlist before the brief goes out. The trigger-phrase pattern is consistent enough that a 90-second read catches most of the risk. The cost of skipping it is a public letter on a government site for the next decade. The downside on running it is one hour. The upside is a roster that never appears in a letter.
We also flag the no-rival window on Marek Health, Mochi Health, and Orderly Meds creators that kills a one-off booking. Here is the pre-publish read we send peptide brands for free.
FAQ
What words actually get flagged in a peptide creator post?
Five buckets show up in FDA warning letters to peptide and compounded GLP-1 brands. Cure or treat language. Clinical-claim language without a doctor on screen. Compounded-as-equivalent-to-Ozempic language. Research-use-only language paired with dosing tips. And weight-loss-amount promises. Each sits on a different surface, and each pulls a different letter.
How long after a post goes live does the warning letter usually arrive?
In the September 2025 FDA sweep of 30 telehealth letters, the public letters cite posts that ran weeks to months earlier. A quiet contact letter often comes first. If the brand does not edit the language, the public letter lands next. The brand has time to fix things if it reads the cue.
Does the FTC treat compounded GLP-1 brands differently than branded Ozempic and Wegovy?
Yes. Branded GLP-1 drugs have an FDA-cleared label that bounds what a creator can say. Compounded GLP-1 brands sit inside the 503A pharmacy exception, the exact surface the FDA targeted in its September 2025 sweep. The compounded path carries the higher letter risk.
Reading loop
Frequently asked
What words actually get flagged in a peptide creator post?
Five buckets show up again and again in FDA warning letters to peptide and compounded GLP-1 brands. Cure or treat language. Clinical-claim language without a doctor on screen. Compounded-as-equivalent-to-Ozempic language. Research-use-only language paired with dosing tips. And weight-loss-amount promises like lose 20 pounds. Each one sits on a different surface of the post, and each pulls a different kind of letter.
How long after a post goes live does the warning letter usually arrive?
In our read of the September 2025 FDA sweep of 30 telehealth letters, the public letters cite posts that ran weeks to months earlier. A quiet contact letter from the FDA often comes first. If the brand does not edit or remove the language, the public warning letter lands next. The full cycle is patient. The brand has time to fix things if it reads the cue.
Does the FTC treat compounded GLP-1 brands differently than branded Ozempic and Wegovy?
Yes. Branded GLP-1 drugs have an FDA-cleared label that bounds what a creator can say. Compounded GLP-1 brands sit inside the 503A pharmacy exception, which is the exact surface the FDA targeted in its September 2025 sweep of 30 telehealth letters. The compounded path carries the higher letter risk in our deal-log read.